Medicago R&D Incorporated
Research
Also recorded in the register as: MEDICAGO R&D INCORPORATED. These spellings have been reviewed and merged onto this page — see data/organisation-aliases.json in the repository.
- Sector
- Companies
- Agreements as applicant
- 1
- In term in September 2026
- 0
- Distinct datasets
- 1
- Files released
- 0
- Latest agreement end date
- 22 March 2022
Sector set by hand: A company, which the register files as Research. See data/organisation-sectors.json in the repository.
Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.
Agreements
| Agreement | Datasets | Files | Latest term | Status | Commercial |
|---|---|---|---|---|---|
| A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older DARS-NIC-436453-C4N4Z | 1 | 0 | 23 March 2021 to 22 March 2022 | Expired | Yes |
Datasets named in its agreements
Cite this page
NHS England (2026) Data Uses Register, September 2026 edition, agreements naming Medicago R&D Incorporated. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/organisations/medicago-r-d-incorporated/ (accessed [date]).
This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.